NEW YORK, Aug. 15, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, announced today that Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development and Regulatory Affairs of NeoStem, has been invited to present at an industry conference next week on the topic of AMR-001, the Company's lead product candidate, in a talk titled "CD34 Stem Cells: Biology's Blueprint for Optimized Interventional Cardiology".
AMR-001 is currently being investigated in the Company's PreSERVE Phase 2 clinical trial, looking at its effect in preserving heart function after a severe heart attack. The trial continues to be on track to complete enrollment in 2013 with data read out 6-8 months after the last patient is infused.
MSC2013: Adult Stem Cell Therapy & Regenerative Medicine
- Date and Time: Wednesday, August 21, 11:45 AM EDT
- Venue: Cleveland Marriott Downtown at Key Center, Cleveland, Ohio
As previously announced, three members of the leadership team of NeoStem's subsidiary, Progenitor Cell Therapy ("PCT"), will also present at an educational lunch symposium at the conference.
About NeoStem
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
For more information, please visit: www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts as well as efforts towards development of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.